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Abstract: 
An isocratic reversed-phase liquid chromatograpic assay method was developed for the quantitative 
determination of fenofibrate and rosuvastatin calcium in bulk and tablet dosage form. A Lichrosphere Select-B 
C8 (250x4.6mm & 5.0μm) column with a mobile phase containing Solution A (Milli-Q water has pH3.0 made by 
orthophosphoric acid): Methanol (20:80). The flow rate was 1.0 mL min−1:  1.5 ml/min and the detection of 
fenofibrate and rosuvastatin calcium was carried out on absorbance detector at 254nm.The retention times was 
12 min (rosuvastatin- 3.40, fenofibrate-7.75). A linear response r2 > 1.0 for fenofibrate in the range of 40-
300μg/ml and r2 > 0.9997 in the range of 2.8-21μg/ml for rosuvastatin calcium was observed. The proposed 
method was validated with respect to system suitability, specificity and selectivity, stability of analytical 
solutions linearity, accuracy, precision, and robustness. The method was successfully applied to the estimation 
of fenofibrate and rosuvastatin calcium in bulk and tablet dosage form.  
Keywords: RP-HPLC, fenofibrate, rosuvastatin calcium, Validation  
Corresponding author: 
Ashutosh Kumar, 
Department of Pharmacology,  
Institute of Medical Sciences, 
Banaras Hindu University,  
Varanasi 221005, India. 
E-mail addresses: ashutoshksingh80@gmail.com  
Please cite this article in press as Rajesh Kumar et al, Simultaneous RP-HPLC Method Development and 
Validation of Fenofibrate and Rosuvastatin Calcium in Bulk and Tablet Dosage Form, Indo Am. J. P. Sci, 
2017; 4(11). 
 
 
 
 
 
 
 
 
 
QR code 
 
 
IAJPS 2017, 4 (11), 4288-4297                  Rajesh Kumar et al                    ISSN 2349-7750 
 w w w . i a j p s . c o m  
 
Page 4289 
INTRODUCTION: 
Rosuvastatin calcium is chemically Bis [(E)-7-[4-
(4-fluorophenyl)-6-isopropyl-2-[methyl 
(methylsulfonyl) amino] pyrimidi-5-yl] (3R, 5S) - 
3, 5-dihydroxyhept-6-enoic acid] calcium. It is used 
in the treatment of Hyperlipidemia. Rosuvastatin 
Calcium is a selective and competitive inhibitor of 
HMG CoA reductase, the rate- limiting enzyme 
that converts 3-hydroxyl-3-methylglutaryl 
coenzyme A to mevalonate, a precursor of 
cholesterol. [1] Fenofibrate is chemically Propane-
2-yl-[4-(4-chlorobenzoyl) phenoxy]-2-methyl 
propanate. It is the lipid regulating drug. It 
increases lipolysis and elimination of triglyceride- 
rich particles from plasma by activating lipoprotein 
lipase and reducing production of apoprotein C-III 
(an inhibitor of lipoprotein lipase activity). [2] 
Literature survey revealed few analytical 
techniques are available for estimation of ROS 
alone as well as in combine dosage form such as 
UV ,HPLC, HPTLC.[3-7] Similarly few analytical 
methods are available for estimation of Fenofibrate 
alone and its combination with drugs such as UV 
and HPLC.[8-17] keeping this objective in mind an 
attempt has been made to develop and validate the 
RP-HPLC method for the simultaneous estimation 
of Rosuvastatin and Fenofibrate which would be 
highly sensitive having good resolution 
reproducible and cost effective. Various validation 
aspects of the analysis accuracy, precision, 
recovery, the limits of detection and quantification 
etc have been measured as per ICH guidelines. [18] 
Chemicals and Reagents  
Rosuvastatin calcium (Active Pharmaceutical 
Ingredient) and working standard were supplied by 
Cadila Healthcare Limited Ankleshwar, India 
whereas fenofibrate (Active Pharmaceutical 
Ingredient) and working standard were supplied by 
Ami Lifesciences Limited Baroda, India. Ortho-
Phosphoric Acid was obtained from Spectrochem 
Pvt. Ltd., India. Acetonitrile was obtained from 
Spectrochem Pvt. Ltd, India. Methanol was 
obtained from Spectrochem Pvt. Ltd., India. Milli-
Q Wateras produced by In-house production of 
company. Triethylamine was obtained from 
Spectrochem Pvt. Ltd, India.      
Chromatographic System 
The HPLC system (Shimadzu Corporation, Japan), 
model Shimadzu VP, consisted of a system 
controller (CLASS-VP), on-line degasser (LC 
2010C, Shimadzu), low pressure gradient valve  
(LC 2010C, Shimadzu), solvent delivery module 
(LC 2010C, Shimadzu), auto injector (LC 2010C, 
Shimadzu), column oven (LC 2010C, Shimadzu), 
and CLASS – VP software version = SPI, binary 
pump, auto injector (SIL-10AD VP, Shimadzu), 
column oven (CTO-10AS VP, Shimadzu) and PDA 
detector (PDA-SPD-M10A VP, Shimadzu Diode 
Array Detector) and Chem station (software) were 
used for analytical purpose. 
 
 
Parameters for method development with Specifications are given in table 1 
Table 1: Parameters for method development 
Parameters Specifications 
Stationary Phase Lichrosphere Select B C8 (250mm x4.6mm) 5 µ. 
Mobile Phase Buffer: Methanol (20:80) 
Diluent Buffer : methanol (20:80) 
ssFlow rate 1.0 ml/min 
Injection volume 10µl 
Detection 254 nm 
Temperature 30˚C 
Run time 12 min (Rosuvastatin- 3.40, Fenofibrate-7.75) 
Buffer Buffer is milliQ water whose pH 3.0made by H3PO4 
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Selection Criteria 
Working Standard and sample from reliable source 
in pure form was collected. Solubility was 
determined of fenofibrate and rosuvastatin calcium 
in appropriate solvent or their mixture of solvents. 
On the basis of solubility studies and literature 
survey, the mobile phase composition for further 
development work was decided. The λmax for 
fenofibrate and rosuvastatin calcium was obtained 
with the help of UV Spectroscopy. Concentration 
or µg/ml solution was prepared for standard by help 
of their label claim mentioned. Selection of column 
carried out on the basis of previous work on 
individual drugs or combination with other drugs, 
mainly C-8 & C-18 column. The column was 
selected on the basis of their retention time, area, 
peak shape and asymmetry. Isocratic mode for the 
analysis was decided by primary run on HPLC 
system. Injection volume was determined on the 
basis of their symmetry and resolution in 
chromatogram by several run on HPLC method.  
Run time was determined on the basis of the 
retention time of both mentioned components. 
Optimization was performed by changing the 
proportion of mobile phase or adjusts the pH of 
mobile phase, as well as trials made on different 
grade column. The mobile phase was selected on 
the basis of resolution, asymmetry, peak shape and 
area. 
Method Development 
Fenofibrate and rosuvastatin calcium showed λmax 
at 254 nm. Proper selection of the HPLC method 
depends upon the nature of the sample (ionic or 
ionizable or neutral molecule), its molecular weight 
and solubility. RP-HPLC was selected for the 
initial separation because of its simplicity and 
suitability. To optimize the chromatographic 
conditions the effect of chromatographic variables 
such as mobile phase, pH, flow rate and solvent 
ratio were studied and the chromatographic 
parameters such as capacity factor, asymmetric 
factor, and resolution and column efficiency were 
calculated. The condition was chosen that gave the 
best resolution and symmetry was selected for 
estimation. The sensitivity of HPLC method that 
uses UV detection depends upon proper selection 
of detection wavelength. An ideal wavelength is the 
one that gives good response for the drugs that are 
to be In the present study, standard solution of 
fenofibrate and rosuvastatin calcium were scanned 
over the range of 200–400 nm wavelengths. The 
both drugs have shown absorbance maxima nearer 
254 nm. So the 254 nm wavelength was selected 
for simultaneous estimation of fenofibrate and 
rosuvastatin calcium in solid dosage forms. For RP-
HPLC method, various columns are available but 
our main aim to resolve the drugs in the presence of 
degradation products and other impurities. So the 
C-8 column was selected over the other columns. 
For fenofibrate and rosuvastatin calcium, 
Lichrosphere Select B C8 (250mm x4.6mm) 5 µ 
column was chosen to give good peak shape and 
high resolution as compared to other C- 8 columns. 
This column has an embedded polar group and 
which are more stable at lower pH and carbon 
loads, which provide high peak purity and more 
retention to polar drugs and facilitates the 
separation of impurity peaks within a very short run 
time.  
 
Method Validation  
Validation was done as per ICH guideline Q2 (R1). 
The developed RP-HPLC methods were validated 
with respect to parameters such as linearity, 
precision, accuracy, specificity, ruggedness, 
robustness and solution stability. [18] 
 
System Suitability 
System suitability is the checking of a system to 
ensure system performance before or during the 
analysis of unknowns. Parameters such as plate 
count, tailing factors, resolution and reproducibility 
(% RSD, retention time and area for six repetitions) 
are determined and compared against the 
specifications set for the method. These parameters 
are measured during the analysis. The Assymetry 
for analyte peak should be not more than (NMT) 
1.2 and % RSD of five replicate standared 
injections should be NMT 2.0.  
 System Precision 
The precision of an analytical method is the degree 
of agreement among individual test results when 
the method is applied repeatedly to multiple 
samplings of homogenous samples. This is usually 
expressed as the standard deviation or the relative 
standard deviation (coefficient of variation). 
Precision is a measure of the degree of 
reproducibility or of the repeatability of the 
analytical method under normal operating 
circumstances. Repeatability involves analysis of 
replicates by the analyst using the same equipment, 
method and conducting the precision study over 
short period of time while reproducibility involves 
precision study at different occasions, different 
laboratories, and different batch of reagent, 
different analysts and different equipments. The 
Standard Solution is prepared at working 
Concentration and analyzed in replicate. The % 
RSD of five replicate standard injection is NMT 
2.0.   
Linearity and Range 
The linearity of an analytical method is its ability to 
elicit test results that are directly (or by a well 
defined mathematical transformation) proportional 
to the analyte concentration in samples within a 
given range. Linearity usually expressed in terms of 
the variance around the slope of regression line 
calculated according to an established 
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mathematical relationship from test results obtained 
by the analysis of samples with varying 
concentrations of analyte. The linear range of 
detect ability that obeys Beer’s law is dependent on 
the compound analyzed and the detector used. 
Linearity was determined at five levels over the 
range of 20% to 150% of test concentration. 
Standard linearity solutions were prepared to 
different concentration of 20%, 50%, 80%, 100%, 
120%, and 150% of the test concentration. Each 
linearity solution was injected in duplicate.  The 
correlation coefficient is should be not less than 
(NLT) 0.995. 
 
Limit of Detection (LOD) and Limit of 
Quantification (LOQ) 
Limit of Detection 
The limit of detection is the parameter of limit 
tests. It is the lowest level of analyte that can be 
detected, but not necessarily determined in a 
quantitative fashion, using a specific method under 
the required experimental conditions. The limit test 
thus merely substantiates that the analyte 
concentration is above or below a certain level. A 
signal-to-noise ratio of 2:1 or 3:1 is generally 
accepted. The signal-to-noise ratio is determined by 
dividing the base peak by the standard deviation of 
all data points below a set threshold. Limit of 
detection is calculated by taking the concentration 
of the peak of interest divided by three times the 
signal-to-noise ratio. The standard deviation of the 
intercept (Sa) which may be related to LOD and the 
slope of the calibration curve, b, by: LOD = 3.3 Sa 
/ b. 
Limit of Quantification 
Limit of Quantification is a parameter of 
quantitative assays for low levels of compounds in 
sample matrices such as impurities in bulk drugs 
and degradation products in finished 
pharmaceuticals. The limit of quantification is the 
lowest concentration of analyte in a sample that 
may be determined with acceptable accuracy and 
precision when the required procedure is applied. It 
is measured by analyzing samples containing 
known quantities of the analyte and determining 
the lowest level at which acceptable degrees of 
accuracy and precision are attainable. The standard 
deviation multiplied by a factor (usually 10) 
provides an estimate of the limit of quantification. 
In many cases, the LOQ is approximately twice the 
limit of detection. Sa is the standard deviation of 
the intercept which may be related to LOQ and the 
slope of the calibration curve, b, by:  LOQ = 10 Sa 
/ b. 
 
Stability of Analytical Solution 
Stability of the sample, standard and reagents is 
required for a reasonable time to generate 
reproducible and reliable results. For example, 24 
hour stability is desired for solutions and reagents 
that need to be prepared for each analysis. System 
suitability test provide the added assurance that on 
a specific occasion the method is giving, accurate 
and precise results. System suitability test are run 
every time a method is used either before or during 
analysis. Solution stability period for standard and 
sample preparation was determined by keeping the 
solution for 12 hour at room temperature. At 
interval 2, 4, 6, 8, 10, and 12 hour the solutions 
were analysed. The insignificant changes (<2%) 
were observed for the chromatographic responses 
for the solution analysed, relative to freshly 
prepared standard. The peak areas of analyte in 
standard and sample solution not differ by more 
than 2% from initial peak area for the accepted 
storage time. 
 
Accuracy  
The accuracy of an analytical method may be 
defined as the closeness of the test results obtained 
by the method to the true value. It is the measure of 
the exactness of the analytical method developed. 
Accuracy may often express as percent recovery by 
the assay of a known amount of analyte added. 
Accuracy may be determined by applying the 
method to samples or mixtures of excipients to 
which known amount of analyte have been added, 
both above and below the normal levels expected in 
the samples. Accuracy is then calculated from the 
test results as the percentage of the analyte 
recovered by the assay. The accuracy of an 
analytical method is the closeness of test results 
obtained by that method to the true value.  The 
accuracy of the method was carried out at three 
levels in the range of 50-150% of the working 
concentration of sample. Calculated amount of 
fenofibrate and rosuvastatin calcium working 
standards were added in placebo containing 
volumetric flasks to prepare 50%, 100% and 150% 
level of the working concentration. Each level was 
prepared in triplicate manner and each preparation 
was injected in duplicate.  The recovery at each 
level should be 98%-102% and the % RSD NMT 
2.0. 
Specificity and Selectivity 
The selectivity of an analytical method is its ability 
to measure accurately and specifically the analyte 
of interest in the presence of components that may 
be expected to be present in the sample matrix. If 
an analytical procedure is able to separate and 
resolve the various components of a mixture and 
detect the analyte qualitatively the method is called 
selective. On the other hand, if the method 
determines or measures quantitatively the 
component of interest in the sample matrix without 
separation, it is said to be specific Specificity is a 
procedure to detect quantitatively the analyte in the 
presence of components that may be expected to be 
present in the sample matrix. While selectivity is 
the procedure to detect qualitatively the analyte in 
IAJPS 2017, 4 (11), 4288-4297                  Rajesh Kumar et al                    ISSN 2349-7750 
 w w w . i a j p s . c o m  
 
Page 4292 
presence of components that may expected to be 
present in the sample matrix. Specificity of 
developed method was established by determining 
peak purity of active component in standard 
preparation, test preparation and spiked sample 
preparation using PDA detector. 
Interference from Blank and Placebo 
A blank preparation, standard preparation, placebo 
preparation, sample preparation of fenofibrate and 
rosuvastatin calcium and placebo spiked with 
targeted concentration of both API were prepared 
and injected. There is no interference from placebo 
with analyte and peak purity of analyte in sample 
solution is NLT 0.995.  
Robustness and Ruggedness 
The robustness of an analytical method is a 
measure of its capacity to remain unaffected by 
small but deliberate variation in method parameters 
and provides an indication of its reliability during 
normal usage. The determination of robustness 
requires that methods characteristic are assessed 
when one or more operating parameter varied. The 
ruggedness of an analytical method is the degree of 
reproducibility of test results obtained by the 
analysis of the same samples under a variety of 
normal test conditions such as different 
laboratories, different analysts, using operational 
and environmental conditions that may differ but 
are still within the specified parameters of the 
assay. The testing of ruggedness is normally 
suggested when the method is to be used in more 
than one laboratory. Ruggedness is normally 
expressed as the lack of the influence on the test 
results of operational and environmental variables 
of the analytical method. % RSD of five replicate 
standard injections should be NMT 2.0.  
 
RESULT AND DISCUSSION: 
System Suitability 
Table 2: System Suitability 
Sr. No.    Parameters 
       (n= 5) 
Fenofibrate Rosuvastatin 
1 Retention Time (min) 
7.45 3.40 
2 Theoritical Plates 
9474.35 5148.93 
3 Asymmetry 
1.11 1.14 
4 % RSD  
0.1825 0.1837 
 
According to above table the all parameters like theoretical plates, assymetry and %RSD was within the limit so 
system is suitable for method. 
System Precision 
Table 3: System Precision 
System precision Injection Area 
 Fenofibrate  
(mV*sec) 
 Rosuvastatin  
(mV*sec) 
Injection 1 
4053570 245539 
Injection 2 
4103144 247064 
Injection 3 
4110290 246958 
Injection 4 
4081802 245988 
Injection 5 
4095113 246368 
% RSD 
0.5 0.3 
Five injections were given and % RSD for both fenofibrate and rosuvastatin calcium was calculated which is 
within the range. 
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Linearity  
The linearity of developed method was achieved in the range of 40-300µg/ml (r2 = 0.9999) for Fenofibrate and 
2.8-21µg/ml (r2 = 0.9999) for Rosuvastatin, The results show that all validation parameters of method lie within 
its specific acceptance crieteria.  
Table 4: Linearity Data of Fenofibrate 
 
Linearity 
Range 
Stock 
solution to be 
taken in ml 
Dilute to 
volume 
(ml)with 
diluent 
Final 
concentration in 
µg/ml 
Fenofibrate 
Area 
20% 1.0 25 40 756662 
50% 2.5 25 100 1964299 
80% 4.0 25 160 3185516 
100% 5.0 25 200 3979271 
120% 6.0 25 240 4774907 
150% 7.5 25 300 5970318 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Linearity Curve for Fenofibrate 
Table 5: Linearity Data of Rosuvastatin Calcium 
Linearity 
Range 
Stock solution to be 
taken in ml 
Dilute to volume (ml)with 
diluent 
Final concentration 
in µg/ml 
Rosuvastatin 
Area 
20% 
2.0 25 2.8 53779 
50% 5.0 25 7.0 137045 
80% 8.0 25 11.2 219267 
100% 10.0 25 14.0 275756 
120% 12.0 25 16.8 328650 
150% 15.0 25 21.0 415303 
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Fig.2: Linearity for Rosuvastatin Calcium 
The mean area at each level was calculated and a graph of mean area versus concentration was plotted. The 
correlation co-efficient, Y intercept and slope of regression line were calculated. 
LOD and LOQ 
Table 6: LOD and LOQ 
Parameters Fenofibrate Rosuvastatin calcium 
Linearity equation Y=20058x-38307 Y=1386x-1945 
Correlation coefficient 1.0 0.9999 
LOD 0.02g/ml 0.02g/ml 
LOQ 0.05g/ml 0.05g/ml 
 
The above data shows that a micro gram quantity of both drugs can be accurately and precisely determined. 
Stability of Analytical Solution 
Table 7: Results of Standard Solution Stability 
Time 
(hour) 
Area % Difference 
Fenofibrtae Rosuvastatin  Fenofibrtae Rosuvastatin 
0 (Initial) 4009869 141792 ----- ------ 
2 4015763 141710 0.1 -0.1 
4  4017140 141875 0.2 0.1 
6 4016521 141787 0.2 0.0 
8  4018345 141758 0.2 0.0 
10 4021270 141729 0.3 0.0 
12  4019958 141583 0.3 -0.1 
14 4024119 141669 0.4 -0.1 
16  4023793 141499 0.3 -0.2 
   %  Mean RSD  0.1825 0.1837 
 
Solution stability lie within its specific acceptance criteria for 12 hrs. 
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Table 8: Results of Sample Solution Stability 
Time 
(hour) 
Area % Difference 
Fenofibrtae Rosuvastatin  Fenofibrtae Rosuvastatin 
0 (Initial) 3960524 151977 ------   ------ 
2 3950322 151328 -0.3 0.4 
4  3952114 151582 -0.2 -0.3 
6 3961673 151907 0.0 0.0 
8  3956805 151754 -0.1 -0.1 
10 3965695 152010 0.1 0.0 
12  3966435 151922 0.1 0.0 
14 3962589 151696 0.1 -0.2 
16  3965523 151764 0.1 -0.1 
                                                                
The solution stability of standard and sample was performed and the percentage difference was not more than 
2%.   
Precision 
Method Precision (Repeatability) 
Table 9: Method Precision Data of Fenofibrate (Feno) and Rosuvastatin calcium (Rosu) 
Set  
No. 
% Assay % Assay                            
Mean  
%RSD 
    
         Feno            Rosu     Feno      Rosu     Feno    Rosu 
1 98.00 101.92  
 
    98.53 
 
 
 
101.00 
 
 
0.30 
 
 
1.20 2 98.67 101.80 
3 98.77 102.21 
4 98.42 100.34 
5 98.50 100.73 
6 98.82 99.01 
Individual % assay, mean % assay and % RSD were calculated. The % RSD is 0.30 for Fenofibrate & 1.20 for 
Rosuvastatin calcium which indicates that the method is precise. 
Intermediate Precision (Ruggedness) 
Table 10: Intermediate Precision Data of Fenofibrate and Rosuvastatin calcium 
Set 
No. 
% Assay % Assay                            
Mean  
%RSD 
 
     Feno        Rosu        Feno      Rosu     Feno      Rosu 
1 98.00 101.87  
 
98.29 
 
 
 
     100.57 
 
 
0.26 
 
 
1.35  
2 98.35 101.31 
3 98.53 101.87 
4 98.10 100.01 
5 98.16 100.02 
6 98.66 98.38 
Individual % assay, mean % assay and % RSD were calculated and recorded in Table10. The % RSD is 0.26 for 
Fenofibrate & 1.35 for Rosuvastatin calcium which indicate that the method is rugged.  
Specificity and Selectivity 
Table 11: Results of Peak Purity in Specificity Study of Fenofibrate and Rosuvastatin calcium 
Sample % Assay Peak purity 
 Fenofibrate Rosuvastatin fenofibrate Rosuvastati 
Standard Solution 100.50 98.21 0.9989 0.9998 
Test Solution 98.42 101.87 0.9992 0.9998 
Spiked Sample  101.65 98.03 0.9998 0.9998 
The peak purity index for the main peak in all the standard preparation, sample and placebo preparation was 
determined there is no interference in main peak.  
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Robustness 
Table 12: Results of Robustness Study 
Compound                                        % RSD (n= 5) 
Normal Condition Changed Condition 
Temperature Normal (-5°C) (+5°C) 
Fenofibrate 0.10 0.02 0.10 
Rosuvastatin 0.10 0.00 0.00 
pH Normal (-0.2 unit) (+0.2 unit) 
Fenofibrate 0.10 0.20 0.10 
Rosuvastatin  0.20 0.10 
Flow Rate Normal (-10%) (+10%) 
Fenofibrate 0.10              0.02 0.01 
Rosuvastatin 0.10                     0.10 0.00 
Mobile phase ratio Normal (-2%) (+2%) 
Fenofibrate 0.10 0.05 0.10 
Rosuvastatin 0.10 0.00 0.10 
Wavelength Normal -5nm +5nm 
Fenofibrate 0.10 0.1 0.05 
Rosuvastatin 0.10 0.00 0.01 
The low % RSD values (< 2%) reveal that the proposed method is robust for this variation. The Summary of 
validation parameters is given in table 13. 
Summary of Validation Results 
Table 13: Summary of Validation Parameters of Fenofibrate and Rosuvastatin calcium by RP-HPLC 
Parameter Acceptance 
Crieteria 
Fenofibrate Rosuvastatin Cal. 
 
Linearity Range 
Correlation 
Coefficient 
Correlation 
coefficient r2 > 0.999 
or 0.995 
40-300µg/ml 
r2 = 0.9999 
2.8-21µg/ml 
r2 = 0.9999 
LOD S/N > 2 or 3 0.02µg/ml 0.02µg/ml 
LOQ S/N > 10 0.05µg/ml 0.05µg/ml 
Precision RSD < 2% %RSD  = 1.2 %RSD  = 0.4 
Intermediate 
Precision 
RSD < 2% %RSD  = 0.8 % RSD = 1.3 
Specificity 1) No intereference 
from blank, placebo 
with the main peak. 
2) The peak purity 
index > 0.999 
No intereference. 
Peak purity 
1)Test sample 
= 0.9992 
2)Spiked sample 
= 0.9998 
No intereference. 
Peak purity 
1)Test sample 
= 0.9998 
2) Spiked sample 
= 0.9998 
 
 
Accuracy Recovery 98- 102% % recovery=101.7 % recovery = 98.2- 101.7 
Solution Stability > 12 hour Stable up to 16 hour 
%RSD = 
Stable up to 16 hour 
%RSD = 
Robustness RSD NMT 2% in 
modified condition 
Complies Complies 
 
CONCLUSION: 
This developed and validated method for 
simultaneous analysis fenofibrate and rosuvastatin 
calcium in pharmaceutical preparations is very 
simple, rapid, accurate and precise. The method 
was successfully applied for determination of 
fenofibrate and rosuvastatin calcium in its 
pharmaceutical formulations. Moreover, it has 
advantages of short run time and the possibility of 
analysis of a large number of samples, both of 
which significantly reduce the analysis time per 
sample. Hence, this method can be conveniently 
used for routine quality control analysis of 
fenofibrate and rosuvastatin calcium in their 
pharmaceutical formulations. 
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